Immunotherapy and Immunoprevention - Molecular Vaccine Design

Nitya Mohan

PhD Student

Phone: +49 6221 42 3822


Scientific CV

Since Aug 2016
PhD student, Immunotherapy and Immunoprevention / Molecular Vaccine Design, DKFZ & DZIF, Heidelberg

Dec 2014 - Jun 2015
Junior Research Fellow, PostGraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

2011 - 2014
MSc (Research) Biology, Tata Institute of Fundamental Research, Mumbai, India

2008 - 2011
BSc Biochemistry, Panjab University, Chandigarh, India

Research Project

Mass spectrometry-based identification of HPV16 target epitopes for therapeutic vaccine design 

The overall aim of the group is to develop a therapeutic vaccine against malignancies and precursor lesions caused by high-risk types of human papillomavirus (HPV). Identification of T-cell epitopes which are presented to the immune system on the surface of transformed cells is essential for rational vaccine development. A highly sensitive targeted nano-flow liquid chromatography mass spectrometry (nano-LC-MS) methodology has been developed in our group for the detection of low-abundant viral epitopes.

This PhD project is aimed at identifying novel HPV16 epitopes for the major human leukocyte antigen (HLA) types, namely HLA-A2, HLA-A3/A11, HLA-A24, HLA-B7 and HLA-B15/A1, which together cover >95% of the world’s population. The final aim is to provide a validated HPV16 epitome map for all these HLA types, to facilitate future immunotherapy design.

Resulting Publications

A targeted LC-MS strategy for low-abundant HLA class-I-presented peptide detection identifies novel human papillomavirus T-cell epitopes.
Blatnik R*, Mohan N*, Bonsack M*, Falkenby LG, Hoppe S, Josef K, Steinbach A, Becker S, Nadler WM, Rucevic M, Larsen MR, Salek M, Riemer AB. * Equal contributors.
Proteomics 2018, 18(11): e1700390.

to top
powered by webEdition CMS